2018 has been an exciting year in world health and our team has spanned the globe to bring you in-depth country reports and high profile interviews with leaders from the life science industry. Bringing you a diverse array of insights – from those spearheading the medical cannabis revolution to the people pioneering precision medicine – here are some of PharmaBoardroom’s best bits…
In this exclusive interview, Lord O’Shaughnessy, parliamentary undersecretary of state for health in the UK, shares with our readers the British way of doing things, from regulation to innovation. We also discuss his predictions for the UK’s Life Science industry post-Brexit.
Keith Thompson is the CEO of the Cell & Gene Therapy Catapult. The catapult model was set up by Innovate UK to support innovation by UK businesses. In this interview from April, Thompson explains the barriers that cell and gene therapies are facing and how the catapult project is helping overcome them.
In Korea, universal healthcare is a top governmental priority. We had a chance to sit down with Yong-Ik Kim, president of the National Health Insurance Services to get his vision and insight into the implementation of the Mooncare reforms, a broad expansion of healthcare coverage.
More on the implementation of universal healthcare, in this exclusive interview, Nicos Anastasiades, president of the Republic of Cyprus talks about the rollout of GESY, a full-coverage healthcare program encompassing the entire nation. President Anastasiades also touches on the importance of the pharmaceutical industry to the country’s economy and his priorities for improving public health.
Maybe the most influential person in the Turkish healthcare ecosystem, Professor Sabahattin Aydın, rector of Medipol University, was dubbed “the man with a plan” during the implementation of universal healthcare in Turkey. In this interview, he lists the practical success factors that have allowed Turkey to become one of the few emerging countries to achieve universal coverage – in record time, as highlighted by the WHO.
More from Turkey on the burning topic of localization, a growing trend in emerging markets around the world. Hakan Yurdakul, head of Economy Monitoring and Coordination from the Presidency Office of the Republic of Turkey discusses the country’s vision, the future dynamics between local and multinational companies and how to boost manufacturing without forgetting R&D.
Thierry Philip, president of Institut Curie in France discusses partnerships with start-ups and industrial partners, handling the hefty price tag of pioneering cancer medicines and his plans as president of the Organisation of European Cancer Institutes (OECI) to build a Europe-wide cancer mission.
Staying in France, we also spoke with Maurice-Pierre Planel, who heads the CEPS, the administration in charge of drug pricing. We discussed the French approach to this critical question and the upcoming changes and adjustments the CEPS is facing.
Brendan Kennedy is the founder and CEO of Tilray, a global leader in medical cannabis research, cultivation, processing and distribution. We discussed his decision, as an American to set up the company in Canada, Big Pharma’s recent interest in the cannabis industry and partnering with Sandoz.
Jacek Glinka, president of Mylan Europe, alongside Tomasz Buczek, Mylan Poland’s country manager, discusses what it means to be an independent global generics company in 2018 and the mounting price pressures in this area of business.
Fadzilah Binti Kamaludin
Dr Fadzilah Kamaludin, the director of the Institute for Medical Research (IMR) in Malaysia, gives us an insight into the important work IMR conducts in the country. She also identifies the challenges inherent in the research environment in Malaysia and prevention strategies for chronic diseases.